X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1053) 1053
science & technology (938) 938
life sciences & biomedicine (862) 862
azepines - therapeutic use (821) 821
animals (742) 742
azepines - pharmacology (693) 693
male (692) 692
female (528) 528
pharmacology & pharmacy (347) 347
adult (319) 319
middle aged (298) 298
mice (297) 297
triazoles - pharmacology (238) 238
azepines - administration & dosage (223) 223
aged (215) 215
rats (198) 198
triazoles - therapeutic use (180) 180
cell line, tumor (172) 172
azepines - adverse effects (158) 158
neurosciences & neurology (149) 149
oncology (147) 147
azepines - chemistry (145) 145
clinical trials as topic (131) 131
dose-response relationship, drug (130) 130
double-blind method (126) 126
neurosciences (121) 121
time factors (114) 114
disease models, animal (110) 110
azepines - pharmacokinetics (100) 100
cell biology (97) 97
proteins (95) 95
analysis (94) 94
cancer (93) 93
cell proliferation - drug effects (93) 93
research (91) 91
adolescent (90) 90
treatment outcome (87) 87
abridged index medicus (85) 85
gene expression (84) 84
platelet activating factor - antagonists & inhibitors (84) 84
biochemistry & molecular biology (82) 82
apoptosis (81) 81
clinical neurology (81) 81
apoptosis - drug effects (80) 80
antineoplastic agents - pharmacology (78) 78
drug therapy (76) 76
health aspects (75) 75
care and treatment (74) 74
sleep initiation and maintenance disorders - drug therapy (73) 73
science & technology - other topics (71) 71
multidisciplinary sciences (69) 69
rats, sprague-dawley (69) 69
research article (69) 69
administration, oral (65) 65
structure-activity relationship (65) 65
xenograft model antitumor assays (65) 65
hypnotics and sedatives - therapeutic use (64) 64
in vitro techniques (64) 64
kinases (63) 63
medicine & public health (63) 63
transcription factors - antagonists & inhibitors (63) 63
antineoplastic agents - therapeutic use (62) 62
chemistry, medicinal (62) 62
meptazinol - therapeutic use (62) 62
transcription factors - metabolism (61) 61
chemistry (60) 60
imidazoles - therapeutic use (60) 60
migraine disorders - drug therapy (58) 58
aurora kinase a - antagonists & inhibitors (57) 57
azepines (57) 57
mice, inbred c57bl (57) 57
azepines - chemical synthesis (56) 56
pyrimidines - pharmacology (56) 56
blood pressure - drug effects (54) 54
nuclear proteins - antagonists & inhibitors (54) 54
pyrimidines - therapeutic use (54) 54
rabbits (54) 54
signal transduction - drug effects (54) 54
enzyme inhibitors - pharmacology (53) 53
young adult (53) 53
alanine - analogs & derivatives (52) 52
azepines - metabolism (52) 52
cell cycle (52) 52
nuclear proteins - metabolism (52) 52
physical sciences (52) 52
psychiatry (52) 52
drug synergism (51) 51
genetic aspects (51) 51
protein kinase inhibitors - pharmacology (51) 51
receptors, calcitonin gene-related peptide - antagonists & inhibitors (51) 51
medicine, research & experimental (50) 50
research & experimental medicine (50) 50
hematology (49) 49
pharmacology/toxicology (49) 49
tumors (49) 49
clinical trials (48) 48
pharmacology (48) 48
random allocation (47) 47
cardiovascular system & cardiology (46) 46
indoles - pharmacology (46) 46
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1395) 1395
German (46) 46
Japanese (35) 35
Italian (26) 26
French (17) 17
Chinese (13) 13
Russian (11) 11
Bulgarian (9) 9
Spanish (7) 7
Polish (3) 3
Swedish (2) 2
Czech (1) 1
Danish (1) 1
Hungarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 05/2016, Volume 2016, Issue 5, pp. CD006103 - CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Interventions to help smokers and other tobacco users to quit | Lungs & airways | Pharmacological interventions | Varenicline | Substance Withdrawal Syndrome | Azepines | Randomized Controlled Trials as Topic | Heterocyclic Compounds, 4 or More Rings | Alkaloids | Quinolizines | Tobacco, drugs & alcohol | By treatment type | Tobacco | Azocines | Bupropion | Benzazepines | Nicotinic Agonists | Counseling | Medications | Medicine General & Introductory Medical Sciences | Nicotine | Smoking | Smoking Cessation | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Humans | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use | Index Medicus
Journal Article
Journal Article
Journal Article